QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook
Q1 2025 preliminary net sales rise 7% CER and adjusted diluted EPS results of at least $0.55 CER both above outlook despite challenging macro environment
Full-year 2025 adjusted diluted EPS outlook raised to about $2.35 CER (prior outlook about $2.28 CER)
On track to exceed 31% CER adjusted operating income margin ahead of 2028 mid-term target
VENLO, Netherlands, April 06, 2025--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary Q1 2025 results that exceeded its outlook for both net sales and adjusted earnings per share (EPS), reflecting strong performances across many growth drivers.
Net sales grew approximately 5% (+7% at constant exchange rates, CER) to about $483 million in Q1 2025, surpassing the previously communicated outlook for about 3% CER growth (4% CER core business excluding discontinued products such as NeuMoDx and Dialunox). Adjusted diluted EPS are expected to be at least $0.55 CER compared to the previously communicated outlook for about $0.50 CER.
Sales of the QuantiFERON latent TB test grew about 15% CER as global adoption continues to shift from the skin test to this proven, modern blood-based test. The QIAstat-Dx syndromic testing system advanced above 35% CER on continued demand for respiratory panels along with growth in gastrointestinal and meningitis testing. The QIAcuity digital PCR system and QIAGEN Digital Insights bioinformatics business both delivered high-single-digit CER gains, reflecting solid adoption across research and clinical applications. Additional growth contributions also came from higher sales of PCR consumables and from OEM products. Sample technologies sales declined 1% CER, reflecting the cautious instrument spending environment among some Life Sciences customers.
Given the positive start to 2025, QIAGEN is raising its adjusted diluted EPS outlook for full-year 2025 in light of the strong sales growth in Q1 and the overall current business trends, which includes expected headwinds from the recently announced U.S. import tariffs and a better-than-expected tax environment.
Full-year 2025, adjusted diluted EPS are now expected to be about $2.35 CER, up from the prior full-year outlook for about $2.28 CER, while reaffirming the goal to improve the adjusted operating income margin to above 30% for the year.
QIAGEN will provide additional perspectives on the outlook for full-year 2025 with the publication of full Q1 2025 results on May 7, 2025.
Additionally, QIAGEN now expects to reach the mid-term adjusted operating income margin goal of at least 31% well ahead of the original 2028 timeline, reflecting the stronger-than-anticipated improvements delivered during 2024 and 2025.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of December 31, 2024, QIAGEN employed more than 5,700 people in over 35 locations worldwide. For more information, visit www.qiagen.com.
Forward-Looking StatementCertain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's financial and operational outlook, including its expected Q1 25 and full year net sales, adjusted diluted EPS and adjusted operating income margin, products, development timelines, marketing and / or regulatory approvals, growth strategies, collaborations and operating results are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, tariffs, regulatory processes and logistical dependencies), variability in operating results and allocations between customer classes, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated financial and operational results will materialize as expected. For a comprehensive overview of risks, please refer to the "Risk Factors" contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.
Source: QIAGENCategory: Corporate
View source version on businesswire.com: https://www.businesswire.com/news/home/20250406144830/en/
Contacts
Contacts QIAGEN: Investor Relations John Gilardi, +49 2103 29 11711Domenica Martorana, +49 2103 29 11244e-mail: ir@QIAGEN.com
Public Relations Thomas Theuringer, +49 2103 29 11826e-mail: pr@QIAGEN.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
Coterra Energy (CTRA) Receives a Buy from Wells Fargo
Wells Fargo analyst Roger Read maintained a Buy rating on Coterra Energy (CTRA – Research Report) on June 20 and set a price target of $31.00. The company's shares closed last Friday at $26.97. Confident Investing Starts Here: According to TipRanks, Read is a 3-star analyst with an average return of 1.7% and a 53.80% success rate. Read covers the Energy sector, focusing on stocks such as Valero Energy, EOG Resources, and Phillips 66. In addition to Wells Fargo, Coterra Energy also received a Buy from Piper Sandler's Mark Lear in a report issued on June 16. However, on June 9, Morgan Stanley maintained a Hold rating on Coterra Energy (NYSE: CTRA). Based on Coterra Energy's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $924 million and a net profit of $516 million. In comparison, last year the company earned a revenue of $1.37 billion and had a net profit of $352 million Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CTRA in relation to earlier this year. Last month, Stephen Bell, the EVP – Business Development of CTRA sold 100,000.00 shares for a total of $2,525,000.00.
Business Wire
2 hours ago
- Business Wire
2025 Travelers Championship Generates More Than $4 Million for Charity
HARTFORD, Conn.--(BUSINESS WIRE)--The Travelers Companies, Inc. (NYSE: TRV) today announced that the 2025 Travelers Championship – a PGA TOUR Signature Event – generated more than $4 million for over 215 nonprofits, both record highs. Travelers also set a record this year as the longest-running title sponsor in the tournament's history. In the 19 years the company has been title sponsor, the Travelers Championship has generated tens of millions of dollars for charity. Alan Schnitzer, Chairman and Chief Executive Officer of Travelers, said, 'This week truly captured what makes the Travelers Championship so special – world-class golf played before an enthusiastic crowd, all united by a shared purpose. It is a formula that led to a great week of golf and more money raised for charity than ever before. For 19 years, we have been honored to bring the PGA TOUR to Connecticut, and every year I am inspired by the passion of the players, the dedication of our fans and the incredible support from volunteers and partners who rally around our mission to give back. In addition to supporting vital charitable causes, we are proud that the tournament also generates significant economic activity for the state of Connecticut. Congratulations to our 2025 champion, Keegan Bradley, for rising to the top of one of the strongest fields in the game. We are already looking forward to making next year's tournament even more memorable.' The Travelers Championship donates 100% of its net proceeds to nonprofits. This year's primary beneficiary is The Hole in the Wall Gang Camp, an organization based in Ashford, Connecticut, that provides a traditional summer camp experience for children with serious illnesses. Many other worthy charities – spanning arts and culture, education, health care, housing, human services, mental health, food insecurity, science and technology, and youth development – also benefit from their involvement with the Travelers Championship. Andy Bessette, Executive Vice President and Chief Administrative Officer of Travelers, said, 'The Travelers Championship extends far beyond tournament week. We have created a community of fans that spans the region, and it is because of their support that we are able to make such an impact on so many charities, the true winners of the Travelers Championship. We are so grateful to the world's best PGA TOUR players for delivering another tremendous competition that we will all remember for some time.' The 2026 Travelers Championship is scheduled to take place June 22-28 at TPC River Highlands in Cromwell, Connecticut. For more information, visit About Travelers
Yahoo
3 hours ago
- Yahoo
Commercial Metals (NYSE:CMC) Will Pay A Dividend Of $0.18
Commercial Metals Company (NYSE:CMC) will pay a dividend of $0.18 on the 9th of July. This payment means the dividend yield will be 1.5%, which is below the average for the industry. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. While yield is important, another factor to consider about a company's dividend is whether the current payout levels are feasible. Prior to this announcement, the company was paying out 113% of what it was earning, however the dividend was quite comfortably covered by free cash flows at a cash payout ratio of only 19%. Given that the dividend is a cash outflow, we think that cash is more important than accounting measures of profit when assessing the dividend, so this is a mitigating factor. Looking forward, earnings per share is forecast to rise exponentially over the next year. Assuming the dividend continues along recent trends, we estimate that the payout ratio could reach 17%, which is in a comfortable range for us. View our latest analysis for Commercial Metals The company has an extended history of paying stable dividends. The dividend has gone from an annual total of $0.48 in 2015 to the most recent total annual payment of $0.72. This means that it has been growing its distributions at 4.1% per annum over that time. While the consistency in the dividend payments is impressive, we think the relatively slow rate of growth is less attractive. Some investors will be chomping at the bit to buy some of the company's stock based on its dividend history. However, initial appearances might be deceiving. Over the past five years, it looks as though Commercial Metals' EPS has declined at around 24% a year. A sharp decline in earnings per share is not great from from a dividend perspective. Even conservative payout ratios can come under pressure if earnings fall far enough. Over the next year, however, earnings are actually predicted to rise, but we would still be cautious until a track record of earnings growth can be built. In summary, while it's good to see that the dividend hasn't been cut, we are a bit cautious about Commercial Metals' payments, as there could be some issues with sustaining them into the future. The company is generating plenty of cash, but we still think the dividend is a bit high for comfort. Overall, we don't think this company has the makings of a good income stock. Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. However, there are other things to consider for investors when analysing stock performance. As an example, we've identified 2 warning signs for Commercial Metals that you should be aware of before investing. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
